<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Bivalirudin,Bivalirudin.png,Antithrombotics,Antithrombotics,ATC code B01,Abciximab,Acenocoumarol,Acetylsalicylic acid,Anaphylaxis,Anatomical Therapeutic Chemical Classification System,Ancrod" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Bivalirudin - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Bivalirudin</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border="0" cellpadding="1" align="right" width="280">
<tr>
<td align="center" colspan="2"><a href="../../../u/p/l/Special%7EUpload_3661.html" class="new" title="Image:Bivalirudin.png">Image:Bivalirudin.png</a></td>
</tr>
<tr>
<td align="center" colspan="2">
<div style="font-size:medium; line-height:167%;">Bivalirudin</div>
</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Systematic (<a href="../../../i/n/t/International_Union_of_Pure_and_Applied_Chemistry_nomenclature_efd4.html" title="International Union of Pure and Applied Chemistry nomenclature">IUPAC</a>) name</b></td>
</tr>
<tr>
<td bgcolor="#EEEEEE" style="text-align: center; vertical-align: top;" colspan="2"><span style="font-size:11px">d-Phenylalanyl-l-prolyl-l-arginyl<br />
-l-prolylglycylglycylglycylglycyl-l-asparaginylglycyl<br />
-l-alpha-aspartyl-l-phenylalanyl<br />
-l-alpha-glutamyl-l-alpha-glutamyl-l-isoleucyl<br />
-l-prolyl-l-alpha-glutamyl-l-isoleucyl<br />
-l-prolyl-l-alpha-glutamyl-l-alpha-glutamyl<br />
-l-tyrosyl-l-leucine</span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Identifiers</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" width="90"><a href="../../../c/a/s/CAS_registry_number_4b20.html" title="CAS registry number">CAS number</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=128270-60-0&amp;rn=1" class="external text" title="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=128270-60-0&amp;rn=1" rel="nofollow">128270-60-0</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../a/n/a/Anatomical_Therapeutic_Chemical_Classification_System_186e.html" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../p/u/b/PubChem_a50b.html" title="PubChem">PubChem</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Chemical data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../c/h/e/Chemical_formula.html" title="Chemical formula">Formula</a></td>
<td bgcolor="#EEEEEE"><a href="../../../c/a/r/Carbon.html" title="Carbon"><span style="color: rgb(000,000,000); font-weight: bold;">C</span></a><sub>98</sub><a href="../../../h/y/d/Hydrogen.html" title="Hydrogen"><span style="color: rgb(154,154,154); font-weight: bold;">H</span></a><sub>138</sub><a href="../../../n/i/t/Nitrogen.html" title="Nitrogen"><span style="color: rgb(000,000,255); font-weight: bold;">N</span></a><sub>24</sub><a href="../../../o/x/y/Oxygen.html" title="Oxygen"><span style="color: rgb(232,070,070); font-weight: bold;">O</span></a><sub>33</sub><sup>&#160;</sup></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../m/o/l/Molecular_mass.html" title="Molecular mass">Mol. mass</a></td>
<td bgcolor="#EEEEEE">2180.3</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Pharmacokinetic data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Bioavailability.html" title="Bioavailability">Bioavailability</a></td>
<td bgcolor="#EEEEEE">100 % (i.v. application only)</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../d/r/u/Drug_metabolism.html" title="Drug metabolism">Metabolism</a></td>
<td bgcolor="#EEEEEE">degraded through proteinases</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Biological_half-life.html" title="Biological half-life">Half life</a></td>
<td bgcolor="#EEEEEE">~25 minutes</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../e/x/c/Excretion.html" title="Excretion">Excretion</a></td>
<td bgcolor="#EEEEEE">&#160;?</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Therapeutic considerations</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../r/e/g/Regulation_of_therapeutic_goods.html" title="Regulation of therapeutic goods">Licence data</a></td>
<td bgcolor="#EEEEEE">
<p><span class="reflink plainlinksneverexpand"><a href="http://www.emea.europa.eu/humandocs/Humans/EPAR/Angiox/Angiox.htm" class="external text" title="http://www.emea.europa.eu/humandocs/Humans/EPAR/Angiox/Angiox.htm" rel="nofollow">EU</a></span>&#160;<span class="reflink plainlinksneverexpand"><a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&amp;SearchTerm=Bivalirudin&amp;SearchType=BasicSearch" class="external text" title="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&amp;SearchTerm=Bivalirudin&amp;SearchType=BasicSearch" rel="nofollow">US</a></span></p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../p/r/e/Pregnancy_category.html" title="Pregnancy category">Pregnancy cat.</a></td>
<td bgcolor="#EEEEEE">
<p>B</p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/e/g/Regulation_of_therapeutic_goods.html" title="Regulation of therapeutic goods">Legal status</a></td>
<td bgcolor="#EEEEEE">
<p>Rx-only. Not a controlled substance.</p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/o/u/Route_of_administration.html" title="Route of administration">Routes</a></td>
<td bgcolor="#EEEEEE">i.v.-injection/infusion only</td>
</tr>
</table>
<p><b>Bivalirudin</b> (<b>Angiomaxâ„¢</b>) is a drug that belongs to the <a href="../../../a/n/t/Anticoagulant.html" title="Anticoagulant">anticoagulant</a> class and acts as a <a href="../../../d/i/r/Direct_thrombin_inhibitor.html" title="Direct thrombin inhibitor">direct thrombin inhibitor</a>.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Basic_chemical_and_pharmacological_properties"><span class="tocnumber">1</span> <span class="toctext">Basic chemical and pharmacological properties</span></a></li>
<li class="toclevel-1"><a href="#Existing_Drug_Forms"><span class="tocnumber">2</span> <span class="toctext">Existing Drug Forms</span></a></li>
<li class="toclevel-1"><a href="#Indications"><span class="tocnumber">3</span> <span class="toctext">Indications</span></a></li>
<li class="toclevel-1"><a href="#Contraindications_and_Precautions"><span class="tocnumber">4</span> <span class="toctext">Contraindications and Precautions</span></a></li>
<li class="toclevel-1"><a href="#Side_Effects"><span class="tocnumber">5</span> <span class="toctext">Side Effects</span></a></li>
<li class="toclevel-1"><a href="#Possible_Interactions"><span class="tocnumber">6</span> <span class="toctext">Possible Interactions</span></a></li>
<li class="toclevel-1"><a href="#Dosage_Regime"><span class="tocnumber">7</span> <span class="toctext">Dosage Regime</span></a></li>
<li class="toclevel-1"><a href="#Comparative_Results"><span class="tocnumber">8</span> <span class="toctext">Comparative Results</span></a></li>
<li class="toclevel-1"><a href="#Conclusions"><span class="tocnumber">9</span> <span class="toctext">Conclusions</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">10</span> <span class="toctext">References</span></a></li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="Basic_chemical_and_pharmacological_properties" id="Basic_chemical_and_pharmacological_properties"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/v/Bivalirudin.html" title="Edit section: Basic chemical and pharmacological properties">edit</a>]</span> <span class="mw-headline">Basic chemical and pharmacological properties</span></h2>
<p>Chemically it constitutes a synthetic congener of the naturally occurring drug <a href="../../../h/i/r/Hirudin.html" title="Hirudin">hirudin</a> (found in the saliva of the <a href="../../../m/e/d/Medicinal_leech.html" title="Medicinal leech">medicinal leech</a> <i>Hirudo medicinalis</i>).</p>
<p>Both bivalirudin and hirudin directly inhibit thrombin by specifically binding as well to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. Thrombin is a serine protease that plays a central role in the thrombotic process, acting to cleave <a href="../../../f/i/b/Fibrinogen.html" title="Fibrinogen">fibrinogen</a> into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing <a href="../../../f/i/b/Fibrin.html" title="Fibrin">fibrin</a> to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.</p>
<p>The pharmacological difference between both drugs is that Hirudin is an irreversible inhibitor of thrombin while Bivalirudin is a reversible one. This leads to a relatively small rate of severe bleedings under Bivalirudin compared to standard therapy (see below under section comparative results).</p>
<p>When delivered by i.v.-infusion with a rate of 2.5 mg/kg/hr, the mean steady-state-concentration is 12.4 Âµg/ml. 80% of the drug is proteolytically cleaved, and the remaining 20% is renally metabolized. The half-life of Bivalirudin is 25 minutes.</p>
<p>The clinical onset of action is almost immediate after i.v.-bolus. Bivalirudin prolongs a number of coagulation parameters due to its mode of action. These are the activated clotting time (ACT), the activated partial thromboplastin time (aPPT), the thrombin time (TT), and the prothrombin time (PTT). After termination of treatment the coagulation parameters return to normal within 1 to 2 hours indicating a short action of Bivalirudin resulting in a good controllability of therapy.</p>
<p><a name="Existing_Drug_Forms" id="Existing_Drug_Forms"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/v/Bivalirudin.html" title="Edit section: Existing Drug Forms">edit</a>]</span> <span class="mw-headline">Existing Drug Forms</span></h2>
<p>In Europe Bivalirudin is sold under the brand name AngioxÂ®, in other countries under AngiomaxÂ® (year of obtained license = 2005 in most countries). The drug is intended for parenteral (i.v.) use only. One vial contains 250mg.</p>
<p>Bivalirudin was licensed due to the results of 2 studies (see below under section comparative results).</p>
<p><a name="Indications" id="Indications"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/v/Bivalirudin.html" title="Edit section: Indications">edit</a>]</span> <span class="mw-headline">Indications</span></h2>
<p>Bivalirudin is indicated to reduce the risk of acute ischemic complications, for example death due to <a href="../../../m/y/o/Myocardial_infarction.html" title="Myocardial infarction">myocardial infarction</a> or need for urgent revascularization procedures, in patients with unstable angina pectoris undergoing <a href="../../../p/e/r/Percutaneous_coronary_intervention.html" title="Percutaneous coronary intervention">percutaneous coronary intervention</a> (PCI). If indicated, the therapy may be continued for up to 4 hours after termination of PCI.</p>
<p><a name="Contraindications_and_Precautions" id="Contraindications_and_Precautions"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/v/Bivalirudin.html" title="Edit section: Contraindications and Precautions">edit</a>]</span> <span class="mw-headline">Contraindications and Precautions</span></h2>
<ul>
<li>The drug must not be given to patients with clinically relevant preexisting bleeding disorders of any origin.</li>
<li>Allergy to Bivalirudin or other ingredients of the preparation.</li>
<li>Women planning to become pregnant (Pregnancy Category B) or wishing to start breast-feeding (effects on the newborn not known) should ask their clinician.</li>
<li>Patients with significantly reduced renal function should receive Bivalirudin in reduced doses.</li>
<li>Pediatric patients should not be treated, because there is no clinical experience.</li>
</ul>
<p><a name="Side_Effects" id="Side_Effects"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/v/Bivalirudin.html" title="Edit section: Side Effects">edit</a>]</span> <span class="mw-headline">Side Effects</span></h2>
<p>The main risk is the occurrence of severe bleedings in 2.4 % of patients in clinical studies. Elderly patients experienced more bleeding episodes than younger patients. Cases of deaths due to severe bleeding attributable to bivalirudin were seen.</p>
<p>Cases of local (skin) or generalized, sometimes severe, <a href="../../../a/n/a/Anaphylaxis.html" title="Anaphylaxis">anaphylactic</a> allergic reactions (including shock) were observed. Isolated cases of death from anaphylactic reactions were seen. <a href="../../../t/h/r/Thrombocytopenia.html" title="Thrombocytopenia">Thrombocytopenia</a> was only infrequently encountered. Unspecific pains and anxiety were frequent but tolerable side-effects.</p>
<p><a name="Possible_Interactions" id="Possible_Interactions"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/v/Bivalirudin.html" title="Edit section: Possible Interactions">edit</a>]</span> <span class="mw-headline">Possible Interactions</span></h2>
<p>When used with other anticoagulants (<a href="../../../h/e/p/Heparin.html" title="Heparin">heparin</a>, <a href="../../../t/h/r/Thrombolytic.html" title="Thrombolytic">thrombolytics</a>, glycoprotein IIB/IIIA blockers, <a href="../../../c/o/u/Coumarin.html" title="Coumarin">coumarins</a>, or <a href="../../../a/s/p/Aspirin.html" title="Aspirin">aspirin</a>), bivalirudin may lead to increased bleeding tendency.</p>
<p><a name="Dosage_Regime" id="Dosage_Regime"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/v/Bivalirudin.html" title="Edit section: Dosage Regime">edit</a>]</span> <span class="mw-headline">Dosage Regime</span></h2>
<p>It is recommended to start therapy with an initial i.v.-loading dose (fast injection) of 0.75 mg/kg followed by i.v.-infusion at a rate of 1.75mg/kg and hour for the duration of PCI. Efficiacy of therapy should be measured during infusion by obtaining the above mentioned coagulation parameters. If necessary, the infusion rate may be increased. After withdrawal of Bivalirudin and normalization of all affected coagulation parameters, further 'minimal anticoagulation', for example with Aspirin, may be indicated.</p>
<p><a name="Comparative_Results" id="Comparative_Results"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/v/Bivalirudin.html" title="Edit section: Comparative Results">edit</a>]</span> <span class="mw-headline">Comparative Results</span></h2>
<p>In a large comparative 30-days study encompassing 6,010 patients (called REPLACE2 study) Bivalirudin was compared with a standard therapy of either <a href="../../../a/b/c/Abciximab.html" title="Abciximab">Abciximab</a> or <a href="../../../e/p/t/Eptifibatide.html" title="Eptifibatide">Eptifibatide</a> plus initial <a href="../../../h/e/p/Heparin.html" title="Heparin">Heparin</a> bolus. The study had a randomized, double-blinded design. Regarding the primary endpoint (death, myocardial infarction, urgent revascularization procedures, severe bleedings) no statistically significant difference between Bivalirudin and standard therapy was noticed (9.2 versus 10.0 %). Regarding ischemic complications (death, myocardial infarction, and urgent revascularization procedures) there was also no statistically significant difference (7.6 vs. 7.1 %). But the risk for severe bleedings was 2.4 % in the Bivalirudin group compared to 4.1 % in the standard therapy-group; a significant difference. In an additional study comparing historical data of Heparin alone (EPISTENT, ESPRIT) with current Bivalirudin results, Bivalirudin gave superior results. Bivalirudin was licensed based on the results of both the REPLACE2 study and the historical data.</p>
<p><a name="Conclusions" id="Conclusions"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/v/Bivalirudin.html" title="Edit section: Conclusions">edit</a>]</span> <span class="mw-headline">Conclusions</span></h2>
<p>Bivalirudin has the potential to become an important anticoagulant during PCI procedures because of the reduced likelihood of severe bleeding as compared with standard therapy. There is ready reversibility of its action after the end of PCI, together with a relatively low frequency of allergic reactions and thrombocytopenia compared with heparin. It is also unnecessary to give other anticoagulants concomitantly with bivalirudin.</p>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../b/i/v/Bivalirudin.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<ul>
<li>AHFS Database online</li>
<li><a href="http://www.pharmazeutische-zeitung.de/index.php?id=121&amp;type=0" class="external free" title="http://www.pharmazeutische-zeitung.de/index.php?id=121&amp;type=0" rel="nofollow">http://www.pharmazeutische-zeitung.de/index.php?id=121&amp;type=0</a> (in German)</li>
<li>Arzenimittel-Datenbank (in German)</li>
<li><a href="http://rx.onconews.org/news/Bivalirudin.html" class="external free" title="http://rx.onconews.org/news/Bivalirudin.html" rel="nofollow">http://rx.onconews.org/news/Bivalirudin.html</a></li>
<li><a href="http://www.emea.europa.eu/humandocs/PDFs/EPAR/angiox/H-562-PI-de.pdf" class="external free" title="http://www.emea.europa.eu/humandocs/PDFs/EPAR/angiox/H-562-PI-de.pdf" rel="nofollow">http://www.emea.europa.eu/humandocs/PDFs/EPAR/angiox/H-562-PI-de.pdf</a> (Document of the European Drug Agency, in German)</li>
</ul>
<table class="navbox collapsible" style="margin: auto;">
<tr>
<th colspan="2" style="text-align:center;">
<div style="float:left; text-align:left; width:6em;">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap;"><a href="../../../a/n/t/Template%7EAntithrombotics_5ce0.html" title="Template:Antithrombotics"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">â€¢</span>&#160;<span style="color: #002bb8;" title="Discussion about this template">d</span>&#160;<span style="font-size:80%;">â€¢</span>&#160;<a href="http://en.wikipedia.org../../../a/n/t/Template%7EAntithrombotics_5ce0.html" class="external text" title="http://en.wikipedia.org../../../a/n/t/Template%7EAntithrombotics_5ce0.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
</div>
Antithrombotics (<a href="../../../t/h/r/Thrombolytic_drug.html" title="Thrombolytic drug">thrombolytics</a>, <a href="../../../a/n/t/Anticoagulant.html" title="Anticoagulant">anticoagulants</a>, and <a href="../../../a/n/t/Antiplatelet_drug.html" title="Antiplatelet drug">antiplatelet drugs</a>) (<a href="../../../a/t/c/ATC_code_B01_f871.html" title="ATC code B01">B01</a>)</th>
</tr>
<tr>
<th style=""><a href="../../../v/i/t/Vitamin_K_6c81.html" title="Vitamin K">Vitamin K</a> antagonists</th>
<td style="" colspan="1"><a href="../../../a/c/e/Acenocoumarol.html" title="Acenocoumarol">Acenocoumarol</a>, Clorindione, <a href="../../../d/i/c/Dicumarol.html" title="Dicumarol">Dicumarol</a> (Dicoumarol), Diphenadione, Ethyl biscoumacetate, <a href="../../../p/h/e/Phenprocoumon.html" title="Phenprocoumon">Phenprocoumon</a>, <a href="../../../p/h/e/Phenindione.html" title="Phenindione">Phenindione</a>, Tioclomarol, <a href="../../../w/a/r/Warfarin.html" title="Warfarin">Warfarin</a></td>
</tr>
<tr>
<th style="">Heparin group<br />
(Platelet aggregation inhibitors)</th>
<td style="" colspan="1"><a href="../../../a/n/t/Antithrombin_III_9434.html" title="Antithrombin III">Antithrombin III</a>, Bemiparin, <a href="../../../d/a/l/Dalteparin.html" title="Dalteparin">Dalteparin</a>, <a href="../../../d/a/n/Danaparoid.html" title="Danaparoid">Danaparoid</a>, <a href="../../../e/n/o/Enoxaparin.html" title="Enoxaparin">Enoxaparin</a>, <a href="../../../h/e/p/Heparin.html" title="Heparin">Heparin</a>, <a href="../../../n/a/d/Nadroparin.html" title="Nadroparin">Nadroparin</a>, Parnaparin, Reviparin, Sulodexide, Tinzaparin</td>
</tr>
<tr>
<th style="">Other&#160;platelet<br />
aggregation&#160;inhibitors</th>
<td style="" colspan="1"><a href="../../../a/b/c/Abciximab.html" title="Abciximab">Abciximab</a>, <a href="../../../a/c/e/Acetylsalicylic_acid.html" title="Acetylsalicylic acid">Acetylsalicylic acid</a> (Aspirin), Aloxiprin, <a href="../../../b/e/r/Beraprost.html" title="Beraprost">Beraprost</a>, Ditazole, Carbasalate calcium, Cloricromen, <a href="../../../c/l/o/Clopidogrel.html" title="Clopidogrel">Clopidogrel</a>, <a href="../../../d/i/p/Dipyridamole.html" title="Dipyridamole">Dipyridamole</a>,<a href="../../../e/p/t/Eptifibatide.html" title="Eptifibatide">Eptifibatide</a>, Indobufen, <a href="../../../i/l/o/Iloprost.html" title="Iloprost">Iloprost</a>, Picotamide, <a href="../../../p/r/a/Prasugrel.html" title="Prasugrel">Prasugrel</a>,<a href="../../../p/r/o/Prostacyclin.html" title="Prostacyclin">Prostacyclin</a>, <a href="../../../t/i/c/Ticlopidine.html" title="Ticlopidine">Ticlopidine</a>, <a href="../../../t/i/r/Tirofiban.html" title="Tirofiban">Tirofiban</a>, <a href="../../../t/r/e/Treprostinil.html" title="Treprostinil">Treprostinil</a>, Triflusal</td>
</tr>
<tr>
<th style="">Enzymes</th>
<td style="" colspan="1"><a href="../../../t/i/s/Tissue_plasminogen_activator.html" title="Tissue plasminogen activator">Alteplase</a>, <a href="../../../a/n/c/Ancrod.html" title="Ancrod">Ancrod</a>, <a href="../../../a/n/i/Anistreplase.html" title="Anistreplase">Anistreplase</a>, Brinase, <a href="../../../d/r/o/Drotrecogin_alfa.html" title="Drotrecogin alfa">Drotrecogin alfa</a>, <a href="../../../f/i/b/Fibrinolysin.html" title="Fibrinolysin">Fibrinolysin</a>, <a href="../../../p/r/o/Protein_C_1c3a.html" title="Protein C">Protein C</a>, <a href="../../../r/e/t/Reteplase.html" title="Reteplase">Reteplase</a>, Saruplase, <a href="../../../s/t/r/Streptokinase.html" title="Streptokinase">Streptokinase</a>, <a href="../../../t/e/n/Tenecteplase.html" title="Tenecteplase">Tenecteplase</a>, <a href="../../../u/r/o/Urokinase.html" title="Urokinase">Urokinase</a></td>
</tr>
<tr>
<th style=""><a href="../../../d/i/r/Direct_thrombin_inhibitor.html" title="Direct thrombin inhibitor">Direct thrombin inhibitors</a></th>
<td style="" colspan="1"><a href="../../../a/r/g/Argatroban.html" title="Argatroban">Argatroban</a>, <strong class="selflink">Bivalirudin</strong>,<a href="../../../d/a/b/Dabigatran.html" title="Dabigatran">Dabigatran</a>, Desirudin, <a href="../../../h/i/r/Hirudin.html" title="Hirudin">Hirudin</a>, <a href="../../../l/e/p/Lepirudin.html" title="Lepirudin">Lepirudin</a>, <a href="../../../m/e/l/Melagatran.html" title="Melagatran">Melagatran</a>, <a href="../../../x/i/m/Ximelagatran.html" title="Ximelagatran">Ximelagatran</a></td>
</tr>
<tr>
<th style="">Other antithrombotics</th>
<td style="" colspan="1"><a href="../../../d/e/f/Defibrotide.html" title="Defibrotide">Defibrotide</a>, <a href="../../../d/e/r/Dermatan_sulfate.html" title="Dermatan sulfate">Dermatan sulfate</a>, <a href="../../../f/o/n/Fondaparinux.html" title="Fondaparinux">Fondaparinux</a>, <a href="../../../r/i/v/Rivaroxaban.html" title="Rivaroxaban">Rivaroxaban</a></td>
</tr>
<tr>
<th style=""><a href="../../../a/n/t/Anticoagulant.html#Anticoagulants_outside_the_body" title="Anticoagulant">Non-medicinal</a></th>
<td style="" colspan="1"><a href="../../../c/i/t/Citrate.html" title="Citrate">Citrate</a>, <a href="../../../e/d/t/EDTA_bb3f.html" title="EDTA">EDTA</a>, <a href="../../../o/x/a/Oxalate.html" title="Oxalate">Oxalate</a></td>
</tr>
</table>

<!-- 
Pre-expand include size: 37649 bytes
Post-expand include size: 15997 bytes
Template argument size: 6572 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../b/i/v/Bivalirudin.html">http://en.wikipedia.org../../../b/i/v/Bivalirudin.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Categories</a>: <span dir='ltr'><a href="../../../h/e/m/Category%7EHematology_8cf0.html" title="Category:Hematology">Hematology</a></span> | <span dir='ltr'><a href="../../../a/n/t/Category%7EAnticoagulants_e341.html" title="Category:Anticoagulants">Anticoagulants</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../b/i/v/Bivalirudin.html">Article</a></li><li id="ca-talk"
	       class="new"	       ><a href="../../../b/i/v/Talk%7EBivalirudin_7c13.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Bivalirudin">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 19:20, 11 March 2007 by Anonymous user(s) of Wikipedia. Based on work by Wikipedia user(s) <a href="../../../s/e/l/User%7ESelket_adc6.html" title="User:Selket">Selket</a>, <a href="../../../t/x/u/User%7ETxuspe_2cf1.html" title="User:Txuspe">Txuspe</a>, <a href="../../../a/x/l/User%7EAxl_2118.html" title="User:Axl">Axl</a>, <a href="../../../w/o/u/User%7EWouterstomp_b006.html" title="User:Wouterstomp">Wouterstomp</a>, <a href="../../../j/f/d/User%7EJfdwolff_9ea6.html" title="User:Jfdwolff">Jfdwolff</a>, <a href="../../../b/l/u/User%7EBluebot_e595.html" title="User:Bluebot">Bluebot</a>, <a href="../../../b/e/t/User%7EBetacommandBot_3654.html" title="User:BetacommandBot">BetacommandBot</a>, <a href="../../../c/o/l/User%7EColin_66ca.html" title="User:Colin">Colin</a>, <a href="../../../k/s/h/User%7EKsheka_e2cf.html" title="User:Ksheka">Ksheka</a>, <a href="../../../k/p/j/User%7EKpjas_9cb5.html" title="User:Kpjas">Kpjas</a>, <a href="../../../e/r/e/User%7EErebus555_1839.html" title="User:Erebus555">Erebus555</a>, KlausFr and <a href="../../../t/r/a/User%7ETravelbird_9a21.html" title="User:Travelbird">Travelbird</a>.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
